OmniAb Inc (OABI) - Long-Term Debt to Capital Coefficient

OmniAb, Inc. (OABI) generates revenue by creating antibodies via transgenic animals, receiving long-term royalties from drug sales. Business growth relies on expanding the client base and patent licensing without utilizing mergers. This chart of the market valuation, where the indicator is 0.06, complements the profile of the brand, which is known for its AI systems that significantly reduce testing timelines for safe medications.

When selecting defensive assets, investors evaluate the stability of the financing structure, where low leverage minimizes default risk. Due to its monopoly position in creating human antibodies and the inelastic demand from pharma behemoths, OmniAb, Inc. (OABI) can effectively manage its debt load, as reflected in the long-term debt-to-equity dynamics, which represent the ratio of liabilities exceeding one year to the company's own equity.